Patents Assigned to Newcastle University Ventures Limited
  • Patent number: 8242077
    Abstract: The invention provides a product comprising: a membrane-spanning protein; a lipid membrane formed from amphiphilic molecules and membrane-spanning protein molecules; and a substrate, wherein the membrane protein is directly coupled to the substrate. The invention also provides a method for producing such a product which i) comprises treating a substrate with a hydrophilic coating agent; ii) providing at least one membrane-spanning protein; iii) bringing the protein into contact with the treated substrate under conditions for the coupling of the protein directly to the treated substrate; and iv) adding amphiphilic molecules to the protein-coupled substrate to form a lipid membrane. The product is useful for biosensors, protein arrays and the like.
    Type: Grant
    Filed: September 16, 2008
    Date of Patent: August 14, 2012
    Assignee: Newcastle University Ventures Limited
    Inventors: Jeremy Hugh Lakey, Horst Vogel
  • Patent number: 7348408
    Abstract: The present invention relates to fusion proteins (fusion polypeptides), particularly for use in expression and/or purification systems. The present inventors have found that the TolAIII domain has remarkable properties which are of particular use as a fusion protein partner to achieve high levels of expression in a host cell. In one aspect of the invention, a TolAIII domain or a functional homologue, fragment, or derivative thereof is located towards the N-terminus of the fusion polypeptide and a non-TolA polypeptide is located towards the C-terminus of the fusion polypeptide.
    Type: Grant
    Filed: January 10, 2003
    Date of Patent: March 25, 2008
    Assignee: Newcastle University Ventures Limited
    Inventors: Isa Gokce, Gregor Anderluh, Jeremy Hugh Lakey
  • Patent number: 7150583
    Abstract: An EKG structure comprising geosynthetic material associated with at least one conducting element wherein the structure comprises at least one core element substantially enclosed by at least one sheath, one or both comprising the geosynthetic material; the use thereof as an electrode, a method for treating substrate with the EKG structure, the treated substance obtained thereby.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: December 19, 2006
    Assignee: Newcastle University Ventures Limited
    Inventors: Robert Colin Pugh, Colin John Francis Philip Jones
  • Publication number: 20060099482
    Abstract: A fuel cell (1) having an electrode comprising an electrocatalyst (32) on a support, wherein the support is a mesh (30) of conductive material such as a metal, metal alloy and metal composite (e.g. titanium or titanium alloy), is disclosed, as well as a method of operating such a fuel cell by contacting a fuel and an oxidant on said electrode. The electrolyte of the fuel cell may be an ion exchange membrane.
    Type: Application
    Filed: August 27, 2003
    Publication date: May 11, 2006
    Applicant: Newcastle University Ventures Limited
    Inventors: Keith Scott, Hua Cheng
  • Publication number: 20040162475
    Abstract: An EKG structure comprising geosynthetic material associated with at least one conducting element wherein the structure comprises at least one core element substantially enclosed by at least one sheath, one or both comprising the geosynthetic material; the use thereof as an electrode, a method for treating substrate with the EKG structure, the treated substance obtained thereby
    Type: Application
    Filed: February 18, 2004
    Publication date: August 19, 2004
    Applicant: Newcastle University Ventures Limited
    Inventors: Robert Colin Pugh, Colin John Francis Philip Jones
  • Patent number: 6736568
    Abstract: An EKG structure comprising geosynthetic material associated with at least one conducting element wherein the structure comprises at least one core element substantially enclosed by at least one sheath, one or both comprising the geosynthetic material; the use thereof as an electrode, a method for treating substrate with the EKG structure, the treated substance obtained thereby
    Type: Grant
    Filed: September 25, 2001
    Date of Patent: May 18, 2004
    Assignee: Newcastle University Ventures Limited
    Inventors: Robert Colin Pugh, Colin John Francis Philip Jones
  • Patent number: 6316455
    Abstract: A range of 3-oxybenzamide compounds and related quinazolinone compounds are disclosed which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DNA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. The coumpounds disclosed include 3-benzyloxybenzamides, 3-oxybenzamides in which a chain of 5 or more methylene groups terminate in a halogen atom or in a purin-9-yl moiety, certain benzoxazole-4-carboxamide compounds and certain quinazolinone compounds. In formula X and Y together may form a bride —X—Y— that represents the grouping (a), (b) or (c) wherein R5 is H, alkyl, aryl or aralkyl.
    Type: Grant
    Filed: November 24, 1999
    Date of Patent: November 13, 2001
    Assignee: Newcastle University Ventures Limited
    Inventors: Roger John Griffin, Alan Hilary Calvert, Nicola Jane Curtin, David Richard Newell, Bernard Thomas Golding
  • Patent number: 6310082
    Abstract: Benzimidazole-4-carboxamide compounds (I) which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DNA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. In formula (I), R and R′ may each be selected independently from hydrogen, alkyl, hydroxyalkyl (e.g. CH2CH2OH), acyl (e.g. acetyl or benzoyl) or an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group. R is generally a substituted phenyl group in the most preferred compounds. The compounds may also be used in the form of pharmaceutically acceptable salts or pro-drugs.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: October 30, 2001
    Assignee: Newcastle University Ventures Limited
    Inventors: Roger J Griffin, Alan H Calvert, Nicola J Curtin, David R Newell, Bernard T Golding
  • Patent number: 6297250
    Abstract: A range of dipyridamole analogues useful for inhibiting transport of nucleosides or purines across cell membranes, thereby to potentiate the activity of various cytotoxic antitumor drugs, is disclosed.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: October 2, 2001
    Assignee: Newcastle University Ventures Limited
    Inventors: Roger J Griffin, Nicola J Curtin, Bernard T Golding, Alan H. Calvert, David R. Newell
  • Patent number: 6156739
    Abstract: Phosphate derivatives are disclosed of quinazolinone compounds having structural formula (I) or a pharmaceutically acceptable salt thereof, wherein X' represent hydroxyl, alkyl, alkoxy, or O--Z where Z is a phosphate or phosphate derivative; Y' represents hydrogen, alkyl or an optionally substituted aryl group or optionally substituted aralkyl group; and R' is hydrogen, alkyl, or CH.sub.2 --O--Z where Z is again a phosphate or phosphate derivative; subject to the proviso that if neither X' nor R' contains Z, Y' is an aryl or aralkyl group having an O--Z substituent therein with Z once again being a phosphate or phosphate derivative as hereinabove defined. These compounds are useful as prodrugs for providing active PARP inhibiting substances for medical use in conjunction with a cytotoxic drug or radiotherapy in order to increase the effectiveness of the latter, especially in connection with antitumor treatment.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: December 5, 2000
    Assignee: Newcastle University Ventures Limited
    Inventors: Roger John Griffin, Alan Hilary Calvert, Jane Nicola Curtin, David Richard Newell, Bernard Thomas Golding
  • Patent number: 6100283
    Abstract: Benzimidazole-4-carboxamide compounds (I) which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DNA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. In formula (I), R and R' may each be selected independently from hydrogen, alkyl, hydroxyalkyl (e.g. CH.sub.2 CH.sub.2 OH), acyl (e.g. acetyl or benzoyl) or an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl or carboxybenzyl) group. R is generally a substituted phenyl group in the most preferred compounds. The compounds may also be used in the form of pharmaceutically acceptable salts or pro-drugs.
    Type: Grant
    Filed: February 2, 1998
    Date of Patent: August 8, 2000
    Assignee: Newcastle University Ventures Limited
    Inventors: Roger John Griffin, Alan Hilary Calvert, Jane Nicola Curtain, David Richard Newell, Bernard Thomas Golding
  • Patent number: 6015827
    Abstract: Benzoxazole carboxamides are disclosed which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DNA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. Representative of the compounds are 2-methyl, 2-t-butyl, 2-phenyl or 2-(4-methoxyphenyl) benzoxazole-4-carboxamide.
    Type: Grant
    Filed: April 8, 1998
    Date of Patent: January 18, 2000
    Assignee: Newcastle University Ventures Limited
    Inventors: Roger John Griffin, Alan Hilary Calvert, Nicola Jane Curtin, David Richard Newell, Bernard Thomas Golding
  • Patent number: 5854240
    Abstract: The encephalopathy caused by ifosfamide and similarly acting compounds can be prevented or treated by the administration of methylene blue or another compound which is able to oxidize a reduced flavin moiety. Pyritinol is able to reduce other aspects of ifosfamide toxicity.
    Type: Grant
    Filed: October 18, 1996
    Date of Patent: December 29, 1998
    Assignee: Newcastle University Ventures Limited
    Inventors: Adrian Kupfer, Thomas Cerny
  • Patent number: 5756510
    Abstract: A range of 3-oxybenzamide compounds and related quinazolinone compounds are disclosed which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DNA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. The compounds disclosed include 3-benzyloxybenzamides, 3-oxybenzamides in which a chain of 5 or more methylene groups terminate in a halogen atom or in a purin-9-yl moiety, certain benzoxazole-4-carboxamide compounds and certain quinazolinone compounds. In formula X and Y together may form a bride --X--Y-- that represents the grouping (a), (b) or (c )wherein R.sup.5 is H, alkyl, aryl or aralkyl.
    Type: Grant
    Filed: August 30, 1996
    Date of Patent: May 26, 1998
    Assignee: Newcastle University Ventures Limited
    Inventors: Roger John Griffin, Alan Hilary Calvert, Nicola Jane Curtin, David Richard Newell, Bernard Thomas Golding